search
Back to results

Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding

Primary Purpose

Overactive Bladder Syndrome, Voiding Dysfunction

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Cystoscopy
Cystoscopy and urethral dilatation
Sponsored by
Medway NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder Syndrome focused on measuring overactive bladder syndrome, voiding, pressure flow studies, urethral dilatation

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. OAB symptoms (based on relevant domains of BFLUTS questionnaire and Urgency Perception Scale) which have not improved with 2 anticholinergic treatments.
  2. Maximum flow rate of less than 15 ml/s on a volume voided of 200mls or more, with a normal or high detrusor pressure at maximum flow on pressure flow studies
  3. Patients must be able to give informed consent for the study

Exclusion Criteria:

  1. Presence of concurrent urodynamic stress incontinence
  2. Patient unfit or unwilling to undergo a general anaesthetic
  3. Patients with bladder pathology or haematuria of unknown origin
  4. Patients with neurological disorders (as these may affect voiding)

Sites / Locations

  • Medway Maritime HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Active Comparator

Arm Label

Cystoscopy alone

Cystoscopy and urethral dilatation

Arm Description

Women in this arm will undergo saline cystoscopy under general anaesthesia only.

Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia

Outcomes

Primary Outcome Measures

Change in pressure flow parameters (voided volume, maximum flow rate, acceleration of flow rate and detrusor pressure at maximum flow) at 6 weeks' post-operatively.
Change in symptoms as measured by the BFLUTS questionnaire and Urgency Perception Scale at 6 weeks' and 6 months' post-operatively.

Secondary Outcome Measures

Change in quality of life status as determined by change in King's Health Questionnaire scoring at 6 weeks and 6 months' post-operatively.

Full Information

First Posted
February 9, 2009
Last Updated
February 9, 2009
Sponsor
Medway NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00839969
Brief Title
Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
Official Title
A Randomized Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
January 2009 (undefined)
Primary Completion Date
October 2009 (Anticipated)
Study Completion Date
October 2009 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Medway NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Urethral dilatation is a commonly undertaken intervention for a variety of urinary complaints including overactive bladder symptoms. There is however very little evidence for its efficacy, and no randomized trial evidence. The aim of this study is to ascertain the effect of urethral dilatation on overactive bladder symptoms and on voiding parameters. The null hypothesis is that there will be no difference in symptoms or voiding parameters between the urethral dilatation and sham groups. Eligible women will be assessed initially with a history and examination, a King's Health Questionnaire and Bristol Female Urinary Tract Symptoms (BFLUTS) questionnaire and pressure flow studies. They will be randomized to undergo either cystoscopy alone or cystoscopy and urethral dilatation. Patients will be blinded to the procedure undertaken and randomized using a series of opaque envelopes. Follow up will be at 6 weeks with repeat questionnaires and pressure flow studies. Subjective and objective outcomes will be compared between the two groups.
Detailed Description
This study is a randomised controlled trial. Objective outcomes will be evaluated at 6 weeks' post-operatively. Subjective outcomes will be evaluated at 6 weeks' and 6 months' post-operatively. Study Population Entry to the study will be offered to all women with OAB symptoms with impaired voiding on cystometry (flow rate less than 15mls/sec with volume of 200mls voided and a normal or high detrusor pressure at maximum flow), who have failed to improve with 2 different anticholinergic medications. Subjects will be recruited from the Urogynaecology clinic at Medway Maritime Hospital. A power calculation was carried out which showed a minimum sample size of 30 (i.e. 15 in each arm) to be necessary to ensure an 80% power with a significance level of 0.05. Pre-operative Assessment All patients will undergo an initial assessment consisting of a full urogynaecogical history and examination, BFLUTS questionnaire and Urgency Perception Scale, and pressure flow studies. As mentioned before, each patient will have been treated with anticholinergic medications prior to being offered this intervention. Surgical Technique All procedures will be carried out under general anaesthesia. A dose of intravenous gentamicin will be given to each patient at induction. After emptying the bladder, saline cystoscopy will be carried out with a 30 degree cystoscope. The bladder mucosa will be systematically inspected for any abnormalities and the bladder filled either until the sphincter mechanism is overcome or to 1000mls. The bladder is emptied again and a second fill undertaken. The bladder mucosa is inspected for petechial haemorrhages, erythema and other signs of chronic cystitis on the second fill. In subjects randomised to undergo urethral dilatation, this will be undertaken using Hagar dilators. There is no evidence in the literature regarding normal urethral calibre in women. Therefore, the urethra will be dilated to a maximum of 10 Hagar as per our unit's protocol. Women will be discharged on the same day, if they pass urine adequately. Post-operative Assessment Subjects will be seen in the Urogynaecology clinic at 6 weeks' post-operatively and assessed with a BFLUTS questionnaire, UPS and repeat pressure flow studies. Each patient will be assessed subjectively at 6 months' post-operatively using the symptom questionnaires. Significance testing will be used to compare symptom scores and pressure flow parameters between each group pre- and post-operatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome, Voiding Dysfunction
Keywords
overactive bladder syndrome, voiding, pressure flow studies, urethral dilatation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cystoscopy alone
Arm Type
Sham Comparator
Arm Description
Women in this arm will undergo saline cystoscopy under general anaesthesia only.
Arm Title
Cystoscopy and urethral dilatation
Arm Type
Active Comparator
Arm Description
Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
Intervention Type
Procedure
Intervention Name(s)
Cystoscopy
Intervention Description
Saline cystoscopy under general anaesthesia
Intervention Type
Procedure
Intervention Name(s)
Cystoscopy and urethral dilatation
Intervention Description
Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
Primary Outcome Measure Information:
Title
Change in pressure flow parameters (voided volume, maximum flow rate, acceleration of flow rate and detrusor pressure at maximum flow) at 6 weeks' post-operatively.
Time Frame
6 weeks
Title
Change in symptoms as measured by the BFLUTS questionnaire and Urgency Perception Scale at 6 weeks' and 6 months' post-operatively.
Time Frame
6 weeks and 6 months
Secondary Outcome Measure Information:
Title
Change in quality of life status as determined by change in King's Health Questionnaire scoring at 6 weeks and 6 months' post-operatively.
Time Frame
6 weeks and 6 months

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: OAB symptoms (based on relevant domains of BFLUTS questionnaire and Urgency Perception Scale) which have not improved with 2 anticholinergic treatments. Maximum flow rate of less than 15 ml/s on a volume voided of 200mls or more, with a normal or high detrusor pressure at maximum flow on pressure flow studies Patients must be able to give informed consent for the study Exclusion Criteria: Presence of concurrent urodynamic stress incontinence Patient unfit or unwilling to undergo a general anaesthetic Patients with bladder pathology or haematuria of unknown origin Patients with neurological disorders (as these may affect voiding)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jonathan Duckett, FRCOG
Phone
+1634 830000
Ext
5154
Email
jonathan.duckett@medway.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan Duckett, FRCOG
Organizational Affiliation
Medway NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medway Maritime Hospital
City
Gillingham
State/Province
Kent
ZIP/Postal Code
ME7 5NY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Duckett, FRCOG
First Name & Middle Initial & Last Name & Degree
Maya Basu, MBBS, BSc(Hons)

12. IPD Sharing Statement

Citations:
PubMed Identifier
23636866
Citation
Basu M, Khullar V, Duckett J. Urethral dilatation: Is there any benefit over cystoscopy and distension? A randomized trial in women with overactive bladder symptoms. Neurourol Urodyn. 2014 Mar;33(3):283-8. doi: 10.1002/nau.22411. Epub 2013 May 1.
Results Reference
derived

Learn more about this trial

Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding

We'll reach out to this number within 24 hrs